Cipla Readies gSymbicort, Semaglutide Amid Sale Speculation ‘Distraction’

"Very Small Investment” In Gene Editing/Sequencing On Cards

Cipla’s US business scales new peak in Q2 amid strong showing overall even as the promoter group stake sale speculation is becoming a 'distraction'. The company has new peptide assets, among others, in the wings while management also points to traction in the 'mRNA journey'.

• Source: Shutterstock

Cipla Limited delivered a strong set of numbers in the second quarter of fiscal 2024 and also outlined pipeline promise, though uncertainty and ongoing speculation around a potential stake sale by the promoter group may be fueling some “distraction” across the ranks. (see side box)

Stake Sale Speculation

Cipla’s senior management gave little away when it came to speculation around the founding Hamied family’s talks for a potential stake sale.(Also see "'Evergreen' Cipla: Chair Hamied Talks New Technologies Amid 'Speculative' Sale News" - Scrip, 11 August, 2023.)

Cipla’s MD and global CEO, Umang Vohra sought to distinguish between the promoters and the company. "We have not heard anything, either way, in terms of the transactions yet. We've been saying that this is speculative from the beginning. We maintain that if there is ever anything that requires a public disclosure, it will be disclosed at that time,” Vohra reiterated at a media briefing.(Also see "Will More Indian Family-Owned Firms Hand Over The Baton To PEs?" - Scrip, 31 July, 2023.)

The executive, though, did indicate that the on-and-off speculation and related uncertainty was leading to some anxiety, though Cipla’s philosophy has always been about investing for the future and “events” should not make a difference to that.

“As a human being, I'm anxious because so many things depend on this decision. Obviously, all of us continuing to work in the organization, that's one big thing,” Vohra said.

“What's more important is just the distraction that this could cause in the business. We're all human beings and get distracted with what happens and that distraction creates difficulties for us in the way we engage with each other and we engage with the organization. That I believe is the biggest impact of this uncertainty”.

Private equity firms and peer Torrent Pharmaceuticals Ltd. have been speculated to be in the fray to acquire a holding in Cipla, though reports in the local media suggest that valuation differences have cropped up stalling, at least for now, Torrent’s most ambitious M&A manoeuvre so far in its long history.(Also see "India M&A Hourglass: Control Deals, ‘FOMO’, Monetization Calls At Family-Owned Firms" - Scrip, 12 September, 2023.)(Also see "Torrent Evasive On Cipla Question, But Comfortable With Domestic Acquisitions" - Scrip, 27 October, 2023.)(Also see "More Interest In Speculated Cipla Stake Sale: Portfolio, Cultural Fit Will Matter" - Scrip, 4 September, 2023.)

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Earnings

Type:DisclosureDevelopments | Publication:GB | Section:Business | Paywall:Free — Article containing all Composer content for testing (Do not update)

 
• By 

Video provides a powerful way to help you prove your point. When you click Online Video, you can paste in the embed code for the video you want to add. You can also type a keyword to search online for the video that best fits your document.

ADHD

This is regarding ADHD.

GB-Business-Free-DisclosureDevelopments-The Secret to Walking More: It’s Not Counting Steps

 
• By 

We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

GB-Business-Free-Podcast-The Secret to Walking More: It’s Not Counting Steps

 
• By 

We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

More from Business

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda - Clone - Clone

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains

ADHD Medications and Cardiovascular Effects: New Data Revealed. (A Comprehensive Evaluation of Emerging Clinical and Epidemiological Evidence on the Cardiovascular Effects Associated with Prescribed Medications for Attention Deficit Hyperactivity Disorder) - Clone

 
• By 

A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.